Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 351 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Injection Site Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Two Injection Sites of Local Anesthetic for Hand Surgery

NCT02112006
View directory record Official record
Conditions
Hand Injury, Wrist Injury, Finger Injury
Interventions
0.5% bupivacaine injected in the forearm, 20-30ml of 0.5% bupivacaine.
Procedure
Lead sponsor
Jose Soberon, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Results available

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
diclofenac sodium topical gel, Placebo
Drug · Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 7, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial

NCT05378113
View directory record Official record
Conditions
Injection Site Irritation
Interventions
Ondansetron, Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors

NCT00765973
View directory record Official record
Conditions
Small Cell Lung Cancer, Ovarian Cancer, Solid Tumors
Interventions
Topotecan Liposomes Injection (TLI)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning

NCT04105283
View directory record Official record
Conditions
Lung Cancer
Interventions
Tc99m-MAA
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

NCT00193037
View directory record Official record
Conditions
Breast Cancer
Interventions
Liposomal Doxorubicin, Docetaxel
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer

NCT04822597
View directory record Official record
Conditions
Breast Cancer, Sentinel Lymph Node, Breast Neoplasms, Breast Cancer Female
Interventions
Lidocaine patch, Buzzy(R), Ice pack
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 7, 2026, 4:41 PM EDT
Recruiting Phase 1 Interventional

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT05504707
View directory record Official record
Conditions
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 7, 2026, 4:41 PM EDT
Not listed Phase 2 Interventional

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

NCT02407600
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Vomiting, Nausea, Emesis
Interventions
FOSAPREPITANT (Emend), Placebo
Drug
Lead sponsor
Ajeet Gajra
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

NCT00361842
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Greenbrae, California • Washington D.C., District of Columbia • Coral Springs, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Early Phase 1 Interventional

A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery

NCT03282461
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 7, 2026, 4:41 PM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 7, 2026, 4:41 PM EDT
Recruiting Phase 2 Interventional

Y-90 Treatment Response Using Transarterial Radioembolization

NCT07145801
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions
Lumason, Sonazoid
Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

NCT01334151
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Insulin LISPRO, recombinant human insulin
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

NCT03188991
View directory record Official record
Conditions
Pancreatic Mucinous-Cystic Neoplasm
Interventions
NanoPac®
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Fort Wayne, Indiana • Columbus, Ohio • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 7, 2026, 4:41 PM EDT
Withdrawn Phase 1 Interventional

Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

NCT00706615
View directory record Official record
Conditions
Breast Cancer
Interventions
Ad-sig-hMUC-1/ecdCD40L vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Topical Ice-therapy for Intravitreal Injections

NCT05269823
View directory record Official record
Conditions
Anesthesia; Hypothermia, Injection Site Irritation
Interventions
Ice-therapy, No Ice-therapy
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 7, 2026, 4:41 PM EDT
Not listed Phase 1 Interventional

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

NCT05539157
View directory record Official record
Conditions
Cutaneous Tumor, Malignant Solid Tumor
Interventions
JCXH-211
Drug
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00096629
View directory record Official record
Conditions
Kidney Cancer
Interventions
human prostate-specific membrane antigen plasmid DNA vaccine, mouse prostate-specific membrane antigen plasmid DNA vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma

NCT00815607
View directory record Official record
Conditions
Melanoma
Interventions
INXN-1001, INXN-3001
Drug · Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Newark, Delaware • Savannah, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions
Proparacaine, Conjunctival culture
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

NCT06366451
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 7, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

NCT00030862
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 7, 2026, 4:41 PM EDT